EUCTR2007-004981-42-SK进行中（未招募）1 期
Phase II study of sunitinib malate (SUTENT®) in relapsed germ cell tumors in males.
arodny onkologicky ustav0 个研究点目标入组 28 人开始时间: 2008年4月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Patients older than 18 years,2. Radiological and/or serological proof of relapsed metastatic germ cell tumor,3. Patient’s disease must not be amenable to cure with either surgery or chemotherapy in the opinion of investigator, 4. Patients have to fail at least two platinum-based regimens or one platinum based regimen in case of platinum-refractory disease or primary mediastinal non-seminomatous germ cell tumor, 5. ECOG performance status: 0-2,6. No previous malignancy, except for basal-cell carcinoma of the skin,7. Adequate organ function: total serum bilirubin <2xULN (exemption are patients with Gilbert disease), serum transaminases <5xULN, serum creatinine <2xULN, serum lipase within normal limits8. Absolute granulocyte count ³ 1,000/mm3, platelets ³ 75,000 mm3, hemoglobin >8g/dl,9. Controlled hypertension,10. At least 4 weeks must have elapsed since the last surgery, radiotherapy and/or chemotherapy before study entry, 11. Complete recovery from prior surgery, and/or reduction of all adverse events from previous systemic therapy or radiotherapy to grade 1, 12. No concurrent treatment with experimental drugs,13. No concurrent chemotherapy,14. No concurrent radiotherapy,15. Measurable disease radiologically and/or according to serum tumor markers,16. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule,17. Signed informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients who do not fit inclusion criteria,2. Female patients,3. Patients infected by the Human Immunodeficiency Virus (HIV),4. Patients with congestive heart failure, myocardial infarction or coronary artery bypass graft in the previous six months, ongoing severe or unstable angina or any unstable arrhytmia requiring medication,5. Patients with other sever acute or chronic medical condition, or laboratory abnormality that would impair, in the judgment of investigator, excess risk associated with study treatment, or which, in judgment of the investigator, would make the patient inappropriate for entry into this study,6. Inability of oral intake, or drug absorbtion (e.g. malabsorption syndrome),7. Hypersensitivity to any compound of the drug,8. Sexually active men not using effective birth control if their partners are women of child-bearing potential.
研究者
相似试验
进行中（未招募）
不适用
Etude de phase II du sunitinib ( SUTENT®) pour le traitement de patients atteints de cancer de la prostate hormono-résistant après progression sous docétaxel. - PROSUTEUCTR2007-003048-31-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
进行中（未招募）
1 期
Phase II study of sunitinib (SU011248) in patients with small cell lung cancer who are either chemo-naïve (extensive disease) or have a sensitive relapsePatients with small cell lung cancer who are either chemo-naïve (extensive disease) or have a sensitive relapse (extensive or limited disease).MedDRA version: 9.1Level: LLTClassification code 10041067Term: Small cell lung cancerEUCTR2006-002485-19-BEEORTC-European Organisation for Research and Treatment of Cancer48
尚未招募
2 期
Phase II study of sunitinib (SU011248) in patients with small cell lung cancer who are either chemo-naïve (extensive disease) or have a sensitive relapsesmall cell lung cancer1003866610029107NL-OMON33984European Organisation for Research in Treatment of Cancer (EORTC)20
进行中（未招募）
不适用
Phase II study of sunitinib (SU011248) in patients with small cell lung cancer who are either chemo-naïve (extensive disease) or have a sensitive relapsePatients with small cell lung cancer who are either chemo-naïve (extensive disease) or have a sensitive relapse (extensive or limited disease).MedDRA version: 9.1Level: LLTClassification code 10041067Term: Small cell lung cancerEUCTR2006-002485-19-DEEORTC-European Organisation for Research and Treatment of Cancer48
进行中（未招募）
1 期
Phase II study of sunitinib (SU011248) in patients with small cell lung cancer who are either chemo-naïve (extensive disease) or have a sensitive relapseEUCTR2006-002485-19-GBEORTC-European Organisation for Research and Treatment of Cancer48